Enable Biosciences Selected for NIH Commercial Accelerator Program

October 9, 2018

Enable Biosciences has been selected from over 300 NIH Phase 2 grant awardees to participate in the 2018 - 2019 National Institutes of Health Commercial Accelerator Program (CAP). Per the NIH: “The CAP is well-regarded for its combination of deep domain expertise and access to industry connections which have resulted in measurable gains and accomplishments by participating companies.” The NIH further describes: “The program enables participants to establish market and customer relevance, build commercial relationships, and focus on revenue opportunities available to them.”

“We are thrilled that the NIH has selected us out of a very competitive field for this critical commercial accelerator program award,” stated Enable’s CEO David Seftel, M.D. “We plan to use the exceptional resources of the program to do a deep dive into the best execution strategy to help bring our early diagnosis system for Type 1 diabetes to customers as soon as possible”

“Type I diabetes is an challenging disease to detect early on. Our ultra-sensitive and highly specific assay technology is designed to directly address this deficit”, explained Enable’s Chief Scientific Officer, Peter Robinson, PhD.

The 2018-2019 CAP also facilitates meetings with the FDA to assist in approval and review. “Our goal is to make our Type 1 diabetes  detection technology available across a range of form factors and platforms to serve the needs of both researchers and clinicians” stated Jason Tsai, PhD, Enable Biosciences’ Chief Technical Officer. He continued: “This way we can help our fellow scientists develop potential interventions that can interrupt this disease at the earliest possible stage, producing a positive impact on the lives of millions of children and young adults, who are most often afflicted with this disease.”

About Enable BiosciencesEnable Biosciences is a San Francisco-based diagnostics company commercializing licensed technology from UC Berkeley and Stanford University. Enable develops ultrasensitive and multiplex immunoassays to help diagnose diseases at their earliest and most effectively treatable stages. For more about Enable, visit www.enablebiosciences.com. For press inquiries, email press@enablebiosciences.com or call Peter Robinson, PhD (415-967-1460).

Enable Biosciences Awarded NIH/NIAID Grant to Advance Minimally-Invasive Multiplex Food Allergy Test Panel

SAN FRANCISCO, Sept. 20, 2018 /PRNewswire/ -- Enable Biosciences Inc. has been awarded a National Institutes of Health/National Institute of Allergy and Infectious Diseases (NIH/NIAID) Small Business Innovation Research (SBIR) Phase I grant for $223,806 to accelerate development of its minimally invasive, ultrasensitive, and specific blood tests for food allergy.

"Food allergies affect up to 9% of the US population, with over 30,000 reactions per year requiring emergency care. For many, especially children, allergic reactions are serious and life-threatening," said David Seftel, MD, MBA, Enable's CEO. "Mitigating and preventing adverse allergic events require accurate diagnosis to direct dietary avoidance, connect patients with novel treatments and to monitor response to treatment."

While existing allergy tests promise a molecular-level analysis of the allergic response, none simultaneously detect many allergies at once while displaying high sensitivity- which is key to detecting allergy early.

"Current tests either detect only one allergy marker at a time at high cost and require collection of large sample volumes or detect many markers at once with a loss of sensitivity. We plan to develop a new high-performance test that doesn't cut corners," added Cheng-ting "Jason" Tsai, PhD, Enable's Chief Technology Officer.

Enable Biosciences is developing a test that detects many allergy markers at once without sacrificing quality. Since it only requires a droplet of blood, it may also improve testing compliance in children.

"The research funded by this grant will produce an enhanced test panel for 80% of the most common food allergens, such as milk, peanut, and shellfish," explained Jesse Cortez, PhD, Senior Scientist at Enable.

The project expands on work between Enable scientists and Stanford co-investigators Stephen Galli, MD and Kari Nadeau, MD, PhD.

About Enable BiosciencesEnable Biosciences is a San Francisco-based diagnostics company commercializing licensed technology from UC Berkeley and Stanford University. Enable develops ultrasensitive and multiplex immunoassays to help diagnose diseases at their earliest and most effectively treatable stages. For more about Enable, visit www.enablebiosciences.com. For press inquiries, email press@enablebiosciences.com or call Peter Robinson, PhD (415-967-1460).

Research reported in this press release is supported by the NIAID of the National Institutes of Health under award number 1 R43 AI141118-01. Content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Scientist Spotlight: Jesse Cortez

Welcome to Enable Biosciences’ Scientist Spotlight. A semi-regular blog post highlighting one of our scientists working to bring Enable’s technology to fruition.

Jesse Headshot for Spotlight.jpg

Tell us a little bit about yourself.

Hi! My name is Jesse Cortez, and I am a lead scientist here at Enable Biosciences. I got my start in science working on carbon nanotubes at Rice University, earned my PhD doing synthetic organic chemistry at UC Berkeley, and most recently spent some time doing a post doctoral fellowship at UCSF. I spent most of my academic career working on becoming a university professor, but then decided to make the jump to work here at Enable. I felt that this small biotech startup was well positioned to make a big difference in the world and I wanted to be a part of that.

Besides my interest in science, I spend my spare time doing local theater! I’ve been singing and dancing since I was very young, and love performing in various musicals around the Bay Area. As recently as 2013 I won the “Best Showtune Cabaret Singer” at a local piano bar (Martuni’s) and have been doing theater ever since. You can see pictures and find out more at my own website www.jessecortezmusic.com!

How did you find Enable?

I actually first found out about Enable Biosciences on Facebook. I saw Peter Robinson (co-founder of Enable) write a post about the new company and that he was looking to hire someone. This came at a time when I was looking for what my job would be after I finished my post-doctoral work.  I attended UC Berkeley around the same time as Peter, and so it was really easy to message him and find out more about the position. After hearing about the amazing technology that Enable Biosciences was working on, I applied for the position and I became the first scientist hired at the company about 2 years ago!

What are you working on at Enable?

I started out doing a lot of the science work that went into validating our ADAP assay

for Type 1 Diabetes and HIV. Now that we have published that work, as a company we want to make sure that our technology can be scaled up to run many samples in one day. Therefore, I’m currently working on being able to run our tests effectively on an automated liquid handling system. I helped write and troubleshoot the programming of our robot which allow us to scale up from the benchtop to a level where we can screen many more people in a day. My next projects involve reducing the time that it takes to run our assay, as well as finding ways to fully barcode our process so that our reagents, samples, and data can be tracked easily. This will be very important in our goal of bringing our assay to market and run an efficient clinical lab. Definitely not what I did my PhD work in, but it has been really fun to learn new skills!

Who is your favorite scientist?

I could give you a legitimate answer like Neil Degrasse Tyson or Arthur C. Cope/Rainer Ludwig Claisen (who discovered the Cope/Claisen sigmatropic rearrangement - my favorite organic reaction), but I think I’ll have to answer Bunson and Beeker from the Muppets!

Enable Biosciences CTO wins Award at American Association of Clinical Chemistry Meeting

AACC Abstract Award.jpg

Enable Biosciences’ Chief Technology Officer Jason Tsai, Ph.D. attended the American Association of Clinical Chemistry (AACC) annual conference July 29–August 2, 2018. Dr. Tsai was honored with the 2018 AACC Industry Division Best Abstract Award for his presentation describing the unique features, performance and benefits of Enable Biosciences’ Antibody Detection by Agglutination-PCR platform as applied to the diagnosis of a range of challenging diseases.

“The AACC is a leading global scientific and medical professional organization dedicated to clinical laboratory science and its application to healthcare. It was a privilege to accept the Best Abstract Award, which highlights the promise that Enable Biosciences’ technology shows for advancing laboratory medicine and clinical care,” said Dr. Tsai, “It is a very exciting time for clinical testing and I am pleased to be a part of a dynamic team that is on the forefront of innovative new diagnostic technologies.”

About the 2018 American Association of Clinical Chemistry Annual Conference in Chicago: The 70th AACC Annual Scientific Meeting & Clinical Lab Expo held July 29–August 2, 2018 was a premiere place where breakthroughs in clinical testing and patient care were introduced to the healthcare world. The meeting attracted global leaders in clinical chemistry, molecular diagnostics, precision medicine, mass spectrometry, translational medicine, lab management, and other major areas of laboratory medicine.

Enable Biosciences Receives $1.5 M Grant from NIH/NIDDK for Type 1 Diabetes Early Detection Test

SAN FRANCISCO, July 31, 2018 /PRNewswire/ -- Enable Biosciences Inc has been awarded a two-year National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) Small Business Innovation Research (SBIR) Phase II grant for $1.5 million to commercialize innovative technology by conducting research and development (R&D) work on low cost and multiplex tests for type 1 diabetes.

Type 1 diabetes (T1D) is an autoimmune disease that affects over a million Americans. Over one in 300 children under age 18 are affected. Up to 40% of new T1D cases coincide with potentially deadly diabetic ketoacidosis (DKA). DKA can be avoided by screening for autoantibody biomarkers, allowing doctors to intervene before major symptoms arise, but tests to detect these markers are generally considered too expensive for screening.

As a part of the award, Enable Biosciences is automating their Antibody Detection by Agglutination-PCR (ADAP) platform to reduce cost and increase throughput. With these improvements, Enable hopes to increase patient access to testing. Earlier detection of pre-diabetic individuals can improve overall care and link patients to clinical trials to potentially slow or halt progression to full type 1 diabetes.

"Developing new technologies to improve the lives of those with type 1 diabetes has been a part of Enable's DNA since its inception. We are pleased to receive NIH/NIDDK support to produce high-quality and accessible tests to allow physicians to intervene earlier and help patients with autoimmune diabetes lead healthier lives," said Cheng-Ting "Jason" Tsai, Ph.D., Chief Technology Officer at Enable Biosciences.

Early Disease Detection Technology Boosted by Phase II National Science Foundation Grant to Enable Biosciences

SAN FRANCISCO, July 17, 2018 /PRNewswire/ -- Enable Biosciences Inc was awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) Phase II grant for $750,000 to commercialize ultrasensitive and multiplexable immunoassays for both research and clinical diagnostic use.

Over 70% of clinical decisions are informed by lab tests, many of which rely on detecting antibody biomarkers. "For hundreds of infectious and autoimmune diseases and cancer, early detection makes the greatest difference to achieve a good outcome. More sensitive and accurate antibody tests are urgently needed," explains Enable's CEO David Seftel, M.D.

The NSF is an independent federal agency with a budget of about $7.5 billion that supports fundamental research and education across all fields of science and engineering.
The NSF is an independent federal agency with a budget of about $7.5 billion that supports fundamental research and education across all fields of science and engineering.
Enable's Antibody Detection by Agglutination-PCR technology (ADAP) is 1,000-10,000 more sensitive at detecting antibodies than existing methods. "Our NSF Phase I grant demonstrated that ADAP could accurately detect dozens of difficult disease markers simultaneously. This Phase II award will help us take this technology from bench to bedside," said Peter Robinson, PhD, Enable's Chief Scientific Officer. Funding from the National Science Foundation will support automation of the testing technology, creation and validation of new tests, ensuring compliance with regulatory standards and developing good manufacturing processes.

"The National Science Foundation supports small businesses with the most innovative, cutting-edge ideas that have the potential to become great commercial successes and make huge societal impacts," said Barry Johnson, Director of Division of Industrial Innovation and Partnerships at NSF.

"We are thrilled to receive this ongoing support from the National Science Foundation," stated Cheng-ting Jason Tsai, PhD, Enable's Chief Technology Officer.

About Enable Biosciences: Enable is a diagnostics company based in San Francisco, CA commercializing licensed technology from UC Berkeley and Stanford University. (www.enablebiosciences.com.) Press inquiries: press@enablebiosciences.com